{
    "clinical_study": {
        "@rank": "4850", 
        "acronym": "OPTIM", 
        "arm_group": {
            "arm_group_label": "Pegasys, injection subcutaneous", 
            "description": "HCV patients monoinfected or coinfected genotype 1/4 treated with Peginterferon alfa-2a and Ribavirin"
        }, 
        "biospec_descr": {
            "textblock": "Whole blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Primary objective:\n\n      \u2022 Develop and validate a tool towards patients with chronic hepatitis C genotype 1 and 4 to\n      allow optimize treatment."
        }, 
        "brief_title": "Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This Tool:\n\n        1. Predicting the overall impact of prognostic factors (including the new factor of\n           genetic polymorphism of the IL28B) on Sustained Viral Response (SVR).\n\n        2. Identify those patients most likely to respond.\n\n        3. Therapy and therefore optimize resources\n\n      The validation tool will check into clinical practice its predictive power (it will consider\n      its ability to calibrate and discriminate) and make correct inferences and interpretations\n      of the scores obtained when applying."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with > 18 years old.\n\n          -  Patients diagnosed with chronic hepatitis C in the presence of HCV RNA in plasma that\n             meet criteria for initiating antiviral therapy in routine clinical practice\n             conditions.\n\n          -  Patients Genotype 1 and 4.\n\n          -  Patients with the results of all the factors evaluable at the time of inclusion.\n\n          -  Patients who have accepted their participation in the study through informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients previously treated with interferon (IFN) and ribavirin (RBV).\n\n          -  Patients with genotype 2, 3, 5 and 6.\n\n          -  Patients with co-infection with hepatitis B.\n\n          -  Patients with other liver diseases.\n\n          -  Patients with any contraindications to the drugs used in the treatment of hepatitis\n             C."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis C genotype 1 and 4 mono-or co-infected with HIV who meet\n        the selection criteria described."
            }
        }, 
        "enrollment": {
            "#text": "770", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884402", 
            "org_study_id": "FPS-PEG-2010-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pegasys, injection subcutaneous", 
                "description": "Treatment as usual clinical practice", 
                "intervention_name": "Peginterferon alfa-2a", 
                "intervention_type": "Drug", 
                "other_name": "Pegasys"
            }, 
            {
                "arm_group_label": "Pegasys, injection subcutaneous", 
                "description": "Treatment as usual clinical practice", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Copegus"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 20, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "FISEVI"
                }, 
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n de la investigaci\u00f3n en salud de Sevilla (FISEVI)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sevilla", 
                        "country": "Spain"
                    }, 
                    "name": "Fundaci\u00f3n P\u00fablica Andaluza para la Gesti\u00f3n de la investigaci\u00f3n en salud de Sevilla (FISEVI)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "1", 
        "official_title": "Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.", 
        "overall_contact": {
            "email": "mromerogomez@us.es", 
            "last_name": "Manuel Romero- Gomez, Medicine"
        }, 
        "overall_official": {
            "affiliation": "Hospital de Valme & ciberEHD", 
            "last_name": "Manuel Romero-G\u00f3mez, Medicine", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Spain: Ethics Committee", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measurement of HCV RNA negativization 24 weeks after treatment", 
            "measure": "Sustained Viral Response (RVS)", 
            "safety_issue": "No", 
            "time_frame": "1 \u00bd years (72 weeks)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884402"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fundaci\u00f3n P\u00fablica Andaluza para la gesti\u00f3n de la Investigaci\u00f3n en Sevilla", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2010", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}